Iberia Pharmaceuticals to open Rs. 70 crore manufacturing unit in India
News

Iberia Pharmaceuticals to open Rs. 70 crore manufacturing unit in India

The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements

  • By IPP Bureau | August 02, 2025

Iberia Pharmaceuticals, a prominent name in skincare, is opening a new 60,000 sq. ft. manufacturing and research facility in Jhajjar, Haryana. The high-tech unit is expected to be operational by mid-2026.

Built with an investment of Rs. 70 crore, the facility is part of the government’s ‘Make-in-India’ initiative and aims to produce science-based, dermatology-focused wellness products.

The unit will feature modern control systems and equipment, supported by an experienced team to ensure smooth large-scale production. It will maintain international quality standards while focusing on cost-effective, compliant, and environmentally sustainable solutions. The facility will cater to customers seeking effective and personalized skincare products.

With a strong focus on research and development, the facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements—all rooted in science.

This new unit complements Iberia’s existing capabilities in clinical-grade, nanotechnology-driven skincare and therapeutic products. All products are vegan and designed for high-performance skincare across various categories.

Nitin Jain, Founder of Iberia Pharmaceuticals, said, “By bringing global manufacturing quality to India, we are building trust and capacity. This plant marks a major milestone in our growth and will meet global regulatory standards. It reflects our commitment to expanding our business and supporting access to high-quality, affordable healthcare.”

At full capacity, the facility will produce over 12 million units annually in dermatology, wellness, and chronic care for both Indian and international markets. It is expected to create more than 600 jobs.

Saurav Ojha, Co-Founder, added, “Iberia is committed to delivering precise, safe, and responsible healthcare solutions. Our new facility reflects this mission and strengthens our focus on research and nanotechnology in skincare.”

Iberia Pharmaceuticals also brings clinically tested, globally recognized brands to India, including Sesderma, Mediderma, Dermpix, Noreva, and Metacare. The products serve individuals, healthcare professionals, and clinics through a curated portfolio.

Upcoming E-conference

Other Related stories

Startup

Digitization